Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

41. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease NIHR DC | Signal - New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 Newer generation anticoagulants appear to reduce the risk of bleeding compared with older (...) anticoagulants like warfarin, when used to prevent clots in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin

NIHR Dissemination Centre2018

42. An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart

An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart NIHR DC | Signal - An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Published on 14 June 2016 Bivalirudin is currently recommended (...) procedures were carried out in the UK. It involves inserting a small tube called a stent into the heart’s arteries, to hold them open. Anticoagulant treatment is needed at the same time to reduce the risk of clotting during and after the procedure. Heparin is the long established anticoagulant, but newer bivalirudin may now be used as an alternative. To date, different trials have produced contradictory evidence comparing the safety and effectiveness of the two anticoagulants when given to patients

NIHR Dissemination Centre2018

44. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines - Anticoagulation During Cardiopulmonary Bypass

The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines - Anticoagulation During Cardiopulmonary Bypass CLINICAL PRACTICE GUIDELINES The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines*—Anticoagulation During Cardiopulmonary Bypass Linda Shore-Lesserson, MD, Robert (...) Management, University of Texas-Southwestern Medical Center, Dallas, Texas; Division of Cardiovascular Perfusion, Medical University of South Carolina, Charleston, South Carolina; Department of Anesthesiology, Saint Anthony Hospital, Lakewood, Colorado; and Department of Cardiothoracic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina Despite more than a half century of “safe” cardiopulmo- nary bypass (CPB), the evidence base surrounding the conduct of anticoagulation therapy for CPB

Society of Thoracic Surgeons2018

45. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury 29519351 2018 03 09 1558-3597 71 10 2018 Mar 13 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. 1105-1113 S0735-1097(18)30092-5 10.1016/j.jacc.2018.01.009 Non-vitamin K antagonist oral anticoagulants (NOACs) are relatively new drugs used for stroke prevention in nonvalvular atrial fibrillation (NVAF). However (...) , Montreal, Quebec, Canada. Electronic address: christel.renoux@mcgill.ca. eng Journal Article United States J Am Coll Cardiol 8301365 0735-1097 atrial fibrillation drug-induced liver injury oral anticoagulants population-based 2017 09 26 2017 12 01 2018 01 01 2018 3 10 6 0 2018 3 10 6 0 2018 3 10 6 0 ppublish 29519351 S0735-1097(18)30092-5 10.1016/j.jacc.2018.01.009

EvidenceUpdates2018

46. Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: A US Hepatologist’s Perspective

Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: A US Hepatologist’s Perspective 29607296 2018 11 14 2450-131X 6 1 2018 Mar Journal of translational internal medicine J Transl Int Med Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: A US Hepatologist's Perspective. 1-5 10.2478/jtim-2018-0001 Northup Patrick G PG MD Center for the Study of Coagulation in Liver Disease, Division of Gastroenterology and Hepatology, University of Virginia

Journal of translational internal medicine2018 Full Text: Link to full Text with Trip Pro

47. Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist’s Perspective

Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist’s Perspective 29607297 2018 11 14 2450-131X 6 1 2018 Mar Journal of translational internal medicine J Transl Int Med Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. 6-10 10.2478/jtim-2018-0002 Riva Nicoletta N Department of Pathology, University of Malta, Msida, Malta. Ageno Walter W Department of Medicine and Surgery, University

Journal of translational internal medicine2018 Full Text: Link to full Text with Trip Pro

48. VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites 29581108 2018 11 14 2473-9537 2 6 2018 03 27 Blood advances Blood Adv VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. 691-702 10.1182/bloodadvances.2017006775 Vitamin K reduction is catalyzed by 2 enzymes in vitro: the vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) and its isozyme VKORC1-like1 (VKORC1L1 (...) ). In vivo, VKORC1 reduces vitamin K to sustain γ-carboxylation of vitamin K-dependent proteins, including coagulation factors. Inhibition of VKORC1 by oral anticoagulants (OACs) is clinically used in therapy and in prevention of thrombosis. However, OACs also inhibit VKORC1L1, which was previously shown to play a role in intracellular redox homeostasis in vitro. Here, we report data for the first time on specific inhibition of both VKOR enzymes for various OACs and rodenticides examined in a cell-based

Blood advances2018 Full Text: Link to full Text with Trip Pro

49. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome Redirecting

Kidney international reports2018 Full Text: Link to full Text with Trip Pro

50. The Significance of Drug—Drug and Drug—Food Interactions of Oral Anticoagulation

The Significance of Drug—Drug and Drug—Food Interactions of Oral Anticoagulation 29636974 2018 11 14 2050-3369 7 1 2018 Mar Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. 55-61 10.15420/aer.2017.50.1 Vitamin K antagonists (VKAs) such as warfarin are the most commonly prescribed oral anticoagulants worldwide. However, factors affecting the pharmacokinetics of VKAs, such as food and drugs, can (...) cause deviations from their narrow therapeutic window, increasing the bleeding or thrombosis risk and complicating their long-term use. The use of direct oral anticoagulants (DOACs) offers a safer and more convenient alternative to VKAs. However, it is important to be aware that plasma levels of DOACs are affected by drugs that alter the cell efflux transporter P-glycoprotein and/or cytochrome P450. In addition to these pharmacokinetic-based interactions, DOACs have the potential for pharmacodynamic

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

51. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia 29467192 2018 11 13 2473-9537 2 4 2018 02 27 Blood advances Blood Adv Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. 381-389 10.1182/bloodadvances.2017013391 Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs (...) employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows

Blood advances2018 Full Text: Link to full Text with Trip Pro

52. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.

Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. OBJECTIVE: To assess the association between anticoagulation, ischaemic stroke, gastrointestinal and cerebral haemorrhage, and all cause mortality in older people with atrial fibrillation and chronic kidney disease. DESIGN: Propensity matched, population based, retrospective cohort analysis from (...) with a previous diagnosis of atrial fibrillation or receiving anticoagulation in the preceding 120 days were excluded, as were patients requiring dialysis and recipients of renal transplants. INTERVENTION: Receipt of an anticoagulant prescription within 60 days of atrial fibrillation diagnosis. MAIN OUTCOME MEASURES: Ischaemic stroke, cerebral or gastrointestinal haemorrhage, and all cause mortality. RESULTS: 6977 patients with chronic kidney disease and newly diagnosed atrial fibrillation were identified

BMJ2018

53. The safety of regional citrate anticoagulation in renal replacement therapy

The safety of regional citrate anticoagulation in renal replacement therapy SAGE Journals: Your gateway to world-class journal research MENU Sign In Institution Society Access Options You can be signed in via any or all of the methods shown below at the same time. My Profile Sign in here to access free tools such as favourites and alerts, or to access personal subscriptions Email (required) Password (required) Remember me I don't have a profile I am signed in as: With my free profile I can: Set

Journal of the Intensive Care Society2018 Full Text: Link to full Text with Trip Pro

54. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation REGULARARTICLE Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial?brillation Surbhi Shah, 1 Faye L. Norby, 2 Yvonne H. Datta, 1 Pamela L. Lutsey, 2 Richard F. MacLehose, 2 Lin Y. Chen, 1 and Alvaro Alonso 3 1 Department of Medicine, Universityof Minnesota Medical School, Minneapolis,MN; 2 Division of Epidemiologyand Community (...) Health, School of Public Health, University of Minnesota, Minneapolis, MN; and 3 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA Key Points ? In AF and cancer pa- tients, rate of bleeding is lower with apixaban, similar in dabigatran and rivaroxaban users, compared to warfarin users. ? Ischemic stroke rates did not differ among anticoagulant users. Incident VTE risk was lower in all DOAC compared with warfarin users

Blood advances2018 Full Text: Link to full Text with Trip Pro

55. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.

Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. Importance: Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH). Objective: To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs (...) ]) and in-hospital mortality among patients with ICH. Design, Setting, and Participants: Retrospective cohort study of 141 311 patients with ICH admitted from October 2013 to December 2016 to 1662 Get With The Guidelines-Stroke hospitals. Exposures: Anticoagulation therapy before ICH, defined as any use of OACs within 7 days prior to hospital arrival. Main Outcomes and Measures: In-hospital mortality. Results: Among 141 311 patients with ICH (mean [SD] age, 68.3 [15.3] years; 48.1% women), 15 036 (10.6%) were

JAMA2018 Full Text: Link to full Text with Trip Pro

56. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. STRENGTH OF RECOMMENDATION: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

PURLS2018

57. Less dementia with oral anticoagulation in atrial fibrillation

Less dementia with oral anticoagulation in atrial fibrillation 29077849 2017 10 27 1522-9645 2017 Oct 24 European heart journal Eur. Heart J. Less dementia with oral anticoagulation in atrial fibrillation. 10.1093/eurheartj/ehx579 The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without (...) oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect. Retrospective registry study of all patients with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014. Propensity score matching, falsification endpoints, and analyses according to intention to treat as well as on-treatment principles were used. The study included 444 106 patients and over 1.5 million years at risk. Patients

EvidenceUpdates2018

58. Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome

Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome 29195825 2018 01 08 1879-1913 121 3 2018 Feb 01 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. 301-307 S0002-9149(17)31692-2 10.1016/j.amjcard.2017.10.035 The significance of adding new oral (...) anticoagulants (NOACs) to antiplatelet therapy in patients with acute coronary syndrome (ACS) is unclear. We conducted a meta-analysis to assess the safety and efficacy of adding NOACs (apixaban, rivaroxaban, and dabigatran) to single antiplatelet agent (SAP) or dual antiplatelet therapy (DAPT) in patients with ACS. Seven randomized controlled trials were selected using PubMed or MEDLINE, Scopus, and Cochrane library (inception to August 2017). The summary measure was random effects hazard ratio (HR) with 95

EvidenceUpdates2018

59. Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study

Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study December 2017 | Volume 4 | Article 85 1 Hypot Hesis and tH eory published: 21 December 2017 doi: 10.3389/fcvm.2017.00085 Frontiers in Cardiovascular Medicine | www.frontiersin.org Edited by: Shimon Rosenheck, Meir Medical Center, Israel Reviewed by: Benjamin Berte, Klinik Im Park, Zurich Javier Eduardo Banchs, Baylor Scott and White Health, United States (...) Marco Proietti, Birmingham University, United Kingdom *Correspondence: Ciro Indolfi indolfi@unicz.it Specialty section: This article was submitted to Cardiac Rhythmology, a section of the journal Frontiers in Cardiovascular Medicine Received: 27 April 2017 Accepted: 08 December 2017 Published: 21 December 2017 Citation: Santarpia G, De Rosa S, Sabatino J, Curcio A and Indolfi C (2017) Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro

60. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants 29296905 2018 11 13 2473-9529 1 26 2017 Dec 12 Blood advances Blood Adv Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. 2536-2540 10.1182/bloodadvances.2017012377 Clinical factors and patient preferences are important for selecting oral anticoagulants for venous thromboembolism (VTE) and atrial fibrillation (AF). The (...) relative association of sociodemographic factors with anticoagulant use is unknown. We evaluated a prospective cohort to compare sociodemographic variables in patients who continued on warfarin for AF or VTE to those who transitioned to 1 of the direct oral anticoagulants (DOACs). Adult patients, newly started on warfarin, were enrolled through 6 anticoagulation clinics across Michigan. Of 8468 patients, 53.3% had AF, 45.6% had VTE, and 1.1% had both. Of these, 696 (8.2%) switched from warfarin

Blood advances2017 Full Text: Link to full Text with Trip Pro